Nykredit A S Invests $9.48 Million in West Pharmaceutical Services, Inc. $WST

Nykredit A S bought a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) during the second quarter, Holdings Channel reports. The institutional investor bought 26,405 shares of the medical instruments supplier’s stock, valued at approximately $9,479,000.

Other institutional investors have also bought and sold shares of the company. Greenleaf Trust boosted its holdings in West Pharmaceutical Services by 4.1% during the 2nd quarter. Greenleaf Trust now owns 843 shares of the medical instruments supplier’s stock worth $303,000 after acquiring an additional 33 shares during the last quarter. Wealth Alliance LLC lifted its position in shares of West Pharmaceutical Services by 3.8% during the 1st quarter. Wealth Alliance LLC now owns 945 shares of the medical instruments supplier’s stock worth $237,000 after buying an additional 35 shares in the last quarter. IFM Investors Pty Ltd grew its stake in West Pharmaceutical Services by 0.3% in the 1st quarter. IFM Investors Pty Ltd now owns 13,773 shares of the medical instruments supplier’s stock valued at $3,452,000 after purchasing an additional 43 shares during the period. Compound Planning Inc. raised its position in West Pharmaceutical Services by 3.6% in the first quarter. Compound Planning Inc. now owns 1,224 shares of the medical instruments supplier’s stock worth $307,000 after acquiring an additional 43 shares during the period. Finally, Aptus Capital Advisors LLC lifted its stake in West Pharmaceutical Services by 5.5% in the fourth quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock valued at $249,000 after purchasing an additional 47 shares during the last quarter. Institutional investors own 93.90% of the company’s stock.

Wall Street Analysts Forecast Growth

WST has been the topic of a number of recent research reports. Stephens restated an “overweight” rating and set a $360.00 price target on shares of West Pharmaceutical Services in a research note on Tuesday, June 2nd. Morgan Stanley boosted their target price on shares of West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. BNP Paribas Exane initiated coverage on West Pharmaceutical Services in a report on Monday, July 13th. They issued an “outperform” rating and a $447.00 price target for the company. Citigroup lifted their price target on West Pharmaceutical Services from $400.00 to $412.00 and gave the company a “buy” rating in a research report on Monday, August 3rd. Finally, KeyCorp boosted their price objective on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a research note on Thursday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, West Pharmaceutical Services has an average rating of “Moderate Buy” and a consensus price target of $368.08.

West Pharmaceutical Services Price Performance

Shares of NYSE:WST opened at $339.90 on Friday. The company’s fifty day moving average price is $350.55 and its 200-day moving average price is $306.92. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. The firm has a market capitalization of $23.92 billion, a price-to-earnings ratio of 43.52, a PEG ratio of 2.38 and a beta of 1.14. West Pharmaceutical Services, Inc. has a one year low of $223.83 and a one year high of $386.00.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The company had revenue of $872.30 million during the quarter, compared to the consensus estimate of $839.98 million. During the same period in the previous year, the firm posted $1.84 EPS. The firm’s revenue was up 13.8% compared to the same quarter last year. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, equities research analysts anticipate that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were paid a dividend of $0.22 per share. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 annualized dividend and a yield of 0.3%. West Pharmaceutical Services’s payout ratio is 11.27%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.